KRAS Oncogene Connect
  • Saved
A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing - Nature Communications

A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing - Nature Communications

Source : https://www.nature.com/articles/s41467-021-26788-6

CRISPR-Cas9 gene editing can induce a p53 mediated damage response. Here the authors investigate the possibility of selection of pre-existing cancer driver mutations during CRISPR-Cas9 knockout based gene editing and...


Conclusion/Relevance:In this study, we systematically investigated the possibility of selection of pre-existing cancer driver mutations during CRISPR-Cas9 gene editing. First, we confirmed and extended upon previous findings that selection13,14,15 of pre-existing p53 mutations by CRISPR-Cas9 can happen, showing it in a large set of transformed...

  • 4yr
    Key Points • Source: Nature Communications • Conclusion/Relevance: “In this study, employing an integrated computational and experimental framework, we systematically investigated the possibility of selection of additional cancer driver mutations during CRISPR-Cas9 gene editing. Show More
  • Saved
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics - PubMed

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34823093/

Widespread identification of KRAS exon 2 p.G12C mutations, especially in cases where NGS is not easily achieved is feasible at a population based level that can characterize regional and national...


Conclusion/Relevance: Widespread identification of KRAS exon 2 p.G12C mutations, especially in cases where NGS is not easily achieved is feasible at a population based level that can characterize regional and national patterns of mutation status. Furthermore, this type of mutation prevalence follows a population substructure pattern that can be...

  • Saved
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations - PubMed

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34820641/

1 Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center,...


Conclusion/Relevance: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.

  • Saved
Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer - PubMed

Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34790385/

c-MET immunohistochemistry was significantly higher in primary tumors with perineural invasion, female gender, and EGFR high expression. However, c-MET-high in the primary tumors was not significantly associated with longer survival...


Conclusions: c-MET immunohistochemistry was significantly higher in primary tumors with perineural invasion, female gender, and EGFR high expression. However, c-MET-high in the primary tumors was not significantly associated with longer survival compared with c-MET-low tumors. Further studies are required to investigate c-MET as potential...

  • Saved
P1‐38: Impact of cisplatin and pemetrexed on VEGFR‐1 on inducing anticancer effects in KRAS‐dependent A549 cells

P1‐38: Impact of cisplatin and pemetrexed on VEGFR‐1 on inducing anticancer effects in KRAS‐dependent A549 cells

Source : https://onlinelibrary.wiley.com/doi/10.1111/resp.14150_38

Background and Aims: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been shown to play a crucial role in cancer progression. This study investigated the anticancer effect of...


Conclusion: Overall, our data suggest that cisplatin monotherapy may be more appropriate than pemetrexed monotherapy or combination therapy, as evidenced by the VEGFR-1 downregulation.